Clinical trials: Patients With Diabetes.
Diabetes Mellitus Type 2
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.
- Trial name
- NCT07020949
- Testing
- THDBH120 injection
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination…
- Trial name
- NCT01076075
- Testing
- Sitagliptin phosphate, Comparator: pioglitazone, Glimepiride or gliclazide
- Volunteers
- 427 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320021
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 80 people
- Sponsor
- BioStratum
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-North (NCT01217476)
- Testing
- Trafermin 0.01% spray
- Where
- 37 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 207 people
- Sponsor
- Olympus Biotech Corporation
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible.
- Trial name
- NCT00300287
- Testing
- Vildagliptin
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Novartis
Diabetic Macular Edema, Diabetic Retinopathy
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma…
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration
- Trial name
- NCT06305416
- Testing
- Ranibizumab 10mg/ml Injection, Lucentis
- Where
- Bangladesh
- Volunteers
- 70 people
- Sponsor
- Incepta Pharmaceuticals Ltd
Type 2 Diabetes Mellitus
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.
- Trial name
- NCT01301833
- Testing
- teneligliptin, glinide, biguanide
- Where
- Japan
- Volunteers
- 462 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus
Safety and Efficacy of YH14617 in Diabetes Mellitus
The objective of this study is to assess the safety, efficacy and pharmacokinetic of YH14617 after once weekly or biweekly injection in patients with type 2 Diabetes Mellitus to investigate the optimal recommended dosage.
- Trial name
- NCT01507038
- Testing
- YH14617
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Yuhan Corporation
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 305 (NCT05504226)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Handok Inc.
T2DM
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of RAY1225 versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- NCT07139535
- Testing
- RAY1225
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic…
- Trial name
- NCT01984606
- Testing
- Empagliflozin, Sitagliptin
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
GDM
Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes
This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes.
- Trial name
- NCT06901791
- Testing
- Conventional treatment and Probiotic
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Diabetes Mellitus, Diabetes Type 1
ACZ885 in Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT01322321
- Testing
- ACZ885
- Where
- 10 sites in United States, Canada and 2 more
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Glufast On Insulin Glargine Trial in Type 2 DM
We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients…
- Trial name
- GLORIA (NCT00663884)
- Testing
- Mitiglinide, Voglibose
- Where
- South Korea
- Volunteers
- 167 people
- Sponsor
- JW Pharmaceutical
Type 1 Diabetes Mellitus
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of sotagliflozin following daily oral administration for 29 days in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01742208
- Testing
- Sotagliflozin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus
Pivotal Omnipod Horizon™ Automated Glucose Control System
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and…
- Trial name
- NCT04196140
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 16 sites in United States
- Volunteers
- 240 people
- Sponsor
- Insulet Corporation
Hypertension, Diabetic Nephropathies
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease.
- Trial name
- NCT00168857
- Testing
- telmisartan, losartan
- Where
- 109 sites in United States, Argentina and 8 more
- Volunteers
- 860 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell…
- Trial name
- NCT00435981
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 8 sites in Sweden
- Volunteers
- 70 people
- Sponsor
- Diamyd Therapeutics AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.